Skip to main content
. 2016 Oct 18;102(2):634–643. doi: 10.1210/jc.2016-1999

Figure 1.

Figure 1.

Vemurafenib treatment in thyroid cancer cells. (A) Activity of vemurafenib detected using MTT assay in BCPAP and FRO cells. IC50 values are shown in brackets behind the name of each cell (nmol/L). Results shown are representative of at least 3 independent experiments. (B) Immunoblots and gel density quantifications against autophagy marker (LC3) in BCPAP and FRO cells. Cells were treated with 5.0 µM vemurafenib (PLX) for the indicated intervals. LC3 (I/II) and GAPDH levels were evaluated by immunoblot analysis. Intensity of LC3I and LC3II were determined by ImageJ densitometry analysis. Bar graphs shown represent normalized intensity levels of LC3II/LC3I relative to no treatment control (0 h). Error bars, SD from 3 independent replicates. #P < 0.05.